(3S,5R,8R,9S,10S,13R,14S,17R)-17-(3-furyl)-10,13-dimethyl-2,3,4,5,6,7, 8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol Suppliers list
|
(3S,5R,8R,9S,10S,13R,14S,17R)-17-(3-furyl)-10,13-dimethyl-2,3,4,5,6,7, 8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol manufacturers
- Rostafuroxin
-
- $15.00 / 1KG
-
2021-07-13
- CAS:156722-18-8
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Rostafuroxin
-
- $15.00 / 1KG
-
2021-07-10
- CAS:156722-18-8
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| (3S,5R,8R,9S,10S,13R,14S,17R)-17-(3-furyl)-10,13-dimethyl-2,3,4,5,6,7, 8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol Basic information |
Product Name: | (3S,5R,8R,9S,10S,13R,14S,17R)-17-(3-furyl)-10,13-dimethyl-2,3,4,5,6,7, 8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol | Synonyms: | (3S,5R,8R,9S,10S,13R,14S,17R)-17-(3-furyl)-10,13-dimethyl-2,3,4,5,6,7, 8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol;Rostafuroxin;PST2238;(3β,5β,14β)-21,23-Epoxy-24-Norchola-20,22-diene-3,14,17-triol;Rostafuroxin (PST-2238);(3beta,5beta,14beta)-21,23-Epoxy-24-norchola-20,22-diene-3,14,17-triol;Rostafuroxin PST2284;(3beta,5beta,14beta)-21,23-Epoxy-24-norchola-20,22-diene-3,14,17-triol Rostafuroxin (PST 2238) | CAS: | 156722-18-8 | MF: | C23H34O4 | MW: | 374.51 | EINECS: | | Product Categories: | Inhibitors | Mol File: | 156722-18-8.mol | |
| (3S,5R,8R,9S,10S,13R,14S,17R)-17-(3-furyl)-10,13-dimethyl-2,3,4,5,6,7, 8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol Chemical Properties |
Boiling point | 451.3±45.0 °C(Predicted) | density | 1.226±0.06 g/cm3(Predicted) | storage temp. | Sealed in dry,Store in freezer, under -20°C | solubility | insoluble in H2O; insoluble in EtOH; ≥12.05 mg/mL in DMSO | form | solid | pka | 14.02±0.70(Predicted) | color | White to off-white |
| (3S,5R,8R,9S,10S,13R,14S,17R)-17-(3-furyl)-10,13-dimethyl-2,3,4,5,6,7, 8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol Usage And Synthesis |
Description | Rostafuroxin potently inhibits binding of endogenous ouabain to the Na+/K+ ATPase (IC50 = 1.7 μM) through the Src-epidermal growth factor receptor (EGFR)-dependent signaling pathway. This blocks the ouabain-dependent increase in Na+/K+ ATPase activity. In cultured renal cells where the Na+/K+ ATPase is upregulated or has increased activity, rostafuroxin normalizes mRNA levels and Na+/K+ ATPase activity. At very low doses (1 and 10 μg/kg for 5-6 weeks) in Milan-hypertensive rats, it decreased the development of hypertension. In a Phase II clinical study, rostafuroxin did not reduce blood pressure in human patients at doses of 0.05-5.0 mg/d. | Uses | (3β,5β,14β)-21,23-Epoxy-24-Norchola-20,22-diene-3,14,17-triol is used as a receptor blocker in the treatment of hypertension. | in vitro | at molecular level, in the kidney, rostafuroxin antagonizes eo by triggering of the src-epidermal growth factor receptor (egfr)-dependent signaling pathway leading to renal na+-k+ pump, and erk tyrosine phosphorylation and activation. in the vasculature, it normalizes the increased myogenic tone caused by nanomolar ouabain [1]. | in vivo | rostafuroxin reduces blood pressure without affecting heart rate, and restores the normal activity of the renal na+-k+-atpase in mhs rats when orally treated at doses from 1 to 100 μg/kg/day. similarly, nua rats have their blood pressure normalized by rostafuroxin [1]. | IC 50 | 2 μm for na+-k+-atpase | storage | Store at +4°C | references | [1] ferrari p, ferrandi m, valentini g, bianchi g. rostafuroxin: an ouabain antagonist that corrects renal and vascular na+-k+-atpase alterations in ouabain and adducin-dependent hypertension. am j physiol regul integr comp physiol. 2006 mar;290(3):r529-35. |
| (3S,5R,8R,9S,10S,13R,14S,17R)-17-(3-furyl)-10,13-dimethyl-2,3,4,5,6,7, 8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol Preparation Products And Raw materials |
|